Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Nerve Repair Pionee | AxoGen leads in peripheral nerve injury solutions, with a growing $5.6 billion market and innovative products driving expansion into new segments like prostate care |
Financial Resilience | Q1 2025 revenue of $48.6M, up 17.4% YoY. Full-year guidance of $215.4M-$219.1M reaffirmed, projecting 15-17% growth. Analysts forecast $248M by 2026 |
Regulatory Catalyst | Anticipated BLA approval for Avance Nerve Graft in September 2025 could boost adoption, secure market exclusivity, and establish it as the standard of care |
Strategic Vision | New CEO Michael Dale's seven-point plan aims for cash flow positivity by 2025-2028, with $70M+ annual operational cash flow by 2028, self-funding future growth |
Metrics to compare | AXGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAXGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −106.7x | −3.9x | −0.5x | |
PEG Ratio | 2.07 | 0.01 | 0.00 | |
Price/Book | 13.0x | 3.5x | 2.6x | |
Price / LTM Sales | 7.4x | 3.4x | 3.2x | |
Upside (Analyst Target) | 23.9% | 42.6% | 49.3% | |
Fair Value Upside | Unlock | 10.0% | 6.3% | Unlock |